Pioneering Tomorrow’s Cures, Today.

Iterion Therapeutics is a clinical-stage, biopharmaceutical company dedicated to revolutionizing healthcare through novel drug discovery and innovation.

Unlocking Hope

At Iterion Therapeutics, we’re developing novel therapeutics for cancer. Our lead product, tegavivint, is a first-in-class, small molecule inhibitor of Transducin Beta-like Protein 1 (TBL1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway.

Drugging the Undruggable

Tegavivint provides a differentiated mechanism to inhibit nuclear beta-catenin, a protein implicated in multiple types of cancers accounting for over 400,000 new cases each year. TBL1 binding to nuclear beta-catenin protects nuclear beta-catenin from degradation and is necessary for oncogenic gene expression. Tegavivint binds to TBL1 in the nucleus, displacing beta-catenin and preventing beta-catenin to TBL1 binding. Free nuclear beta-catenin is then degraded, inhibiting downstream oncogenic gene transcription.

Tegavivint in the Clinic

Iterion is enrolling a company-sponsored clinical trial in hepatocellular carcinoma, an indication where ~40% of patients harbor a Wnt/beta-catenin mutation and there is significant unmet clinical need. Iterion has already established tegavivint safety, pharmacodynamic, and clinical activity in a completed Phase 1 clinical trial.

The company also has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials.

Get in touch with Iterion


2450 Holcombe Blvd.
Houston, TX 77021

First Name
Last Name
The form has been submitted successfully!
There has been some error while submitting the form. Please verify all form fields again.
Scroll to Top